We report the results of a preclinical study comparing four different purging protocols using a promyelocytic human cell line HL-60 and myeloid leukemic progenitor cells (colonyforming unit-leukemic [CFU-L]) from acute myelogenous leukemia (AML) patients assayed in semisolid culture. We studied the antileukemic effect of (1) 
M therapy followed by autologous bone marrow (BM)
rescue, may be curative for patients with acute myelogenous leukemia (AML) lacking a suitable HLA-matched BM donor.'" However, tumor cell contamination of reinfused marrow could be a potential source of relapse in these patients. Recent experiments and clinical trials demonstrated the feasibility of ex vivo treatment of human BM. '-4 Yeager et alz have reported encouraging results in patients with AML who were transplanted in second or third remission with 4-hydroperoxycyclophosphamide purged marrow, the disease-free survival (43%) being similar to that obtained with allogeneic transplantation. Although 4-HC or 4-HC + VP-16 protocols have been found to be effective for purging leukemia cells from the marrow grafts,'r3 the combination of different purging techniques might be more effective in eliminating tumor cells. Based on this premise, we compared four purging protocols using the promyelocytic human cell line HL-60 and myeloid leukemic progenitor cells (colony-forming unit-leukemic [CFU-L]) from AML patients assayed in semisolid culture. In particular, we studied the colonyforming inhibition activity of complement-mediated lysis by two monoclonal antibodies (MoAbs) (directed toward CD33 and CD13 antigens); 4-HC used alone or combined with VP-16; and a cocktail of MoAbs plus 4-HC + VP-16 treatment. We showed that purging was not complete after MoAbs + C' procedure or drug treatment while combined immunochemotherapy provided the highest tumor cell killing. As no in vitro hemopoietic colonies (ie, CFUgranulocyte-macrophage [CFU-GM], burst-forming uniterythroid [BFU-E]) were observed in most of the experiments after treatment of normal light-density marrow cells with the combined immunochemotherapy, we assessed the recovery of colony-forming cells (CFU-GM) derived from patients with AML, we observed a mean value of CFU-L inhibition of 92.3% f 2.5% SD, 95.5% f 1.4% SD, and 99% * 0.8% SD after MoAbs and complement lysis, 4-HC, and 4-HC + VP-16 treatment, respectively. The combined treatment of MoAbs and 4-HC + VP-I6 produced more than 3-log reduction of CFU-L colony formation. By comparison, the mean recovery of committed normal bone marrow progenitors after incubation with MoAbs and complement was 12% for CFU-granulocyte-macrophage (CFU-GM), 22 .9% for burstforming unit erythroid (BFU-E), and the recovery following 4-HC + VP-16 treatment was 4.4% for CFU-GM and 5.6%
BFU-E. In subsequent experiments, highly purified CD34' blast cells, enriched by positive selection, and stimulated in liquid culture by cytokines (interleukin- 
MATERIALS AND METHODS
Human cell line. HL-60 is a human acute promyelocytic leukemia cell line growing with a doubling time of 24 hours and a plating efficiency (PE) of 7% to 12%.'' The cell line was maintained in exponential growth in RPMI-1640 supplemented with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 1% penicillin-streptomycinneomycin (PSN; GIBCO, Chagrin Falls, OH), and 1% L-glutamine at 37°C in a humidified atmosphere of 5% CO, air. Cell viability was always higher than 95% and cells were free of mycoplasma contamination.
EM cells. BM was aspirated from the posterior iliac crest of healthy volunteers after obtaining written informed consent and BM mononuclear cells were collected after Ficoll-Hypaque gradient (1.077 g/cm').
Cells were obtained from peripheral blood (PB) of eight AML patients ( Table 1 ). The diagnosis of AML was established by morphologic criteria, cytochemical staining, and by surface-marker analysis using a panel of MoAbs. Leukemic specimens were subclassifed according to the French-American-British (FAB) classification system." If the platelet count was sufficiently high, the blood was first depleted of platelets by centrifugations over Percoll (1.050 g/cm') (Pharmacia Fine Chemicals Co, Piscataway, NJ), and light-density cells were subsequently obtained by centrifugation over Percoll (1.075 picm'). The leukemic cells were suspended in FCS and cryopreserved using a mixture containing 5% dimethyl sufoxide (DMSO) and 6% hydroxyethyl starch (HES) as described." Cells were frozen at -120°C in a Revco Freezer (Revco Scientific, Asheville, NC). After thawing, the cells were suspended in lscove's modified Dulbecco's medium (IMDM) supplemented with 10% FCS (Hyclone) and 60 UimL of Deoxyribonuclease 1 (DNAse) (Cooper Biomedical, Malvern, PA) and incubated for 30 minutes on ice. Viable cells were recovered by Ficoll-Hypaque gradient. All samples contained more than 86% of blasts and promyelocytes ( Tumor cells and normal BM cells were adjusted to a concentration of 2 x 106/mL and 20 x 106/mL, respectively. Drugs and MoAbs were added in a single incubation: VP-16 was used at the concentration of 5 &mL; 4-HC, 80 Fmol/L or 100 kmol/L; M195 and F23, 40 pg/mL while the optimal complement (baby rabbit complement; Pel Freez, Brown Deer, WI) concentration was found to be 1:6 (volfvol). After completion of 1 hour of incubation at 3 7 T , the cells were put on ice for 5 minutes and washed twice with RPMI supplemented with FCS. To simulate ex vivo BM purging conditions, the HL-60 cells were also incubated together with irradiated (3,000 cGy) BM cells antibiotics, and 1% L-glutamine. The number of cells plated in 1 mL of medium was 1,000 untreated and l@ treated. Cells were incubated at 37°C in humidifed atmosphere of 5% CO, in air and scored for colonies ( > 50 cells) after 7 days of incubation using an inverted microscope.
After treatment, normal BM cells were assayed for colonies derived from CFU-GM, BFU-E, and CFU-GEM as already de- For personal use only. on October 23, 2017. by guest www.bloodjournal.org From utes of incubation with HPCA-1 (MY10, 10 pg/mL, Becton Dickinson) as reported elsewhere." The percentage of CD34+ blasts, evaluated by morphologic analysis and immunoflurescence was 1% to 4% before purging procedures, 10% to 15% after purging, and always higher than 90% after immunopanning. CD34* cells, 5 x lo4, were plated in semisolid medium for CFU-GM with recombinant granulocyte-macrophage colonystimulating factor (rGM-CSF) (1,000 U/mL; Amgen, Thousand Oaks, CA), interleukin-3 (IL-3) (50 ng/mL; Genetics Institute, Cambridge, MA), or MoCM (lo%, vol/vol) as colony-stimulating factor. Colonies were counted after 14 days of incubation with an inverted microscope and recorded as the Day 0 (DO) CFU-GM frequency. Simultaneously, 1 x lo5 cells were suspended in 1 mL of IMDM supplemented with 20% FCS containing IL-3 (50 ng/mL) or IL-3 + IL-1 (100 U/mL; Syntex, Palo Alto, CA) or MoCM (10% volhrol). On day 7, cells were counted and 1 x lo4 cells from each suspension were plated for CFU-GM in triplicate as described above. Fourteen-day colonies were recorded as D7 CFU-GM frequency, because 7 days elapsed from the beginning of the liquid culture. The Delta value is determined by dividing the D7 CFU-GM frequency by the DO CFU-GM frequency, and it is an indicator of the number of progenitors of earlier stage than the 14-day CFU-GM. When DO CFU-GM value was zero, the D7 CFU-GM frequency was divided by 0.33 because the clonogenic assay was set up in triplicate and one colony was the lower limit of detection.
Data ana&sk. All experiments were performed three or more times and the mean ? standard deviation (SD) values of each experiment were calculated. Colony counts after drug treatment were expressed as a percent of the untreated control cells.
RESULTS

Effect of chemotherapy andlor immunotherapy on tumor cells.
Blood and/or marrow specimens from 50 AML patients were screened for the development of 10-day CFU-L-derived colonies induced by MoCM: 78% of AML patients generated CFU-L present at 10 days." Eight patients were chosen for the study on the basis of adequate colony growth and their clinical characteristics are reported in Table 1 (Fig 1) .
Eight AML patients were treated according to the four protocols. The results are shown in Fig 2. No CFU-L (ie, Table 2 . The low number of CFU-GEM observed in our experiments did not allow any statistical analysis; therefore, only the results of CFU-GM and BFU-E recovery are reported. The single treatments showed a mean recovery of 12% CFU-GM and 22.9% of BFU-E (immunotherapy), and 4.4% CFU-GM and 5.6% BFU-E (chemotherapy). The colony-forming efficiency of hematopoietic cells was completely abolished by the combined protocol in most of the experiments. When 4-HC was tested at the concentration of 80 pmolL and combined with VP-16 and MoAbs, the recovery of CFU-GM and BFU-E was 2.7% 2 3% SD and 1% +-2.5% SD, respectively (data not shown in Table) . Additional experiments were then designed to assess the recovery of progenitor cells from enriched population of CD34' cells after immunopharmacologic treatment. Our assay consisted of the stimulation of the pre-CFU-GM (CD34') compartment by rCSFs or MoCM in liquid culture followed by a clonogenic assay to evaluate the recovery of CFU-GM derived from the enriched blast population. We also compared different culture conditions to investigate the optimal combination of CSFs for stimulating early hematopoietic progenitors. In this set of experiments, the addition of the MoAb F23 to the combined treatment did not give different results than the MoAb M195 used alone with drugs; therefore, only the data of M195 plus 4-HC + VP-16 protocol are reported in Table 3 . In the first three experiments, IL-3 alone (experiments 1 and 2) or combined with IL-1 (experiments 1,2, and 3) and MoCM were chosen as stimulating factors in the suspension culture while GM-CSF and IL-3 were used for inducing CFU-GM growth in the semisolid assay. These three experiments did not show any CFU-GM recovery after the immunopharmacologic treatment before enrichment of CD34+ cells by immunopanning. When CD34' cells were assayed, we observed few CFU-GM in two experiments (1 and 3) (DO value) and no granulocyte-macrophage progenitors were obtained in experiment 2. The number of CFU-GM colonies scored after 1 week of liquid culture (D7 value) was remarkably higher than the DO value specifically following stimulation in suspension culture with MoCM using either GM-CSF or IL- For personal use only. on October 23, 2017. by guest www.bloodjournal.org From on AML cells demonstrated that phenotypic features are acquired in an analogous manner to their normal counterp a r t~.~' ,~~ Therefore, the lack of a specific MoAb that reacts on the leukemic cells is the major obstacle for this procedure. In addition, the heterogeneity in antigen expression on CFU-L could allow some leukemic cells to escape lysis.34
To improve current purging methods, we attempted to remove occult leukemic cells from autologous marrow by combining two different purging methods. In particular, a multiagent chemotherapeutic protocol (4-HC + VP-16) was compared and combined with complement-mediated lysis by two MoAbs broadly reactive with myeloid cells (anti-CD33 and anti-CD-13).
A similar approach (ie, immunochemotherapy) has been already proposed for purging of T-cell acute lymphocytic leukemia (T-ALL) and Burkitt's lymphoma cells providing a significant increase in tumor cell killing when compared with the single treatment although the results of normal BM recovery have not been reported in the first s t~d y .~' .~~ The 4-HC + VP-16 (100 Fmol/L and 5 pglmL, respectively) purging protocol has proven to have a synergistic activity on HL-60 cells and antagonistic on normal BM precursors," and it is being used as a purging treatment for AML and non-Hodgkin lymphoma patients at Memorial M195 MoAb recognizes CD33 antigen (p67) and it was found expressed on most of the myeloblastic leukemias studied. M195 and rabbit complement were able to eliminate almost all of the committed BM progenitors in a clonogenic assay (ie, 14-day CFU-GM and BFU-E) while no binding of 1251 M195 was found on early blast cells collected by negative selection.2L These observations could suggest a therapeutic advantage for a protocol involving the use of M195 (alone or combined with an anti-CD13 M o m , namely F23) that is positive on the majority of Ah4L cells but not on the earliest normal colony-forming cells. A similar MoAb, MY9, also reactive with CD33 antigen has been used to purge AML patients marrows from residual leukemic cells. '6 In our experimental system HL-60 leukemic cell line clonogenic efficiency was reduced more than 4 logs, in presence of marrow cell excess, after 1 hour of incubation with M195 plus 4-HC + VP-16 while the treatment with chemotherapy or immunotherapy alone was less effective on clonogenic tumor cells. The same combined protocol produced, at a sensitivity level of 3 logs, a complete eradication of CFU-L from eight patients with AML. The addition of F23 MoAb did not further enhance the elimination of both HL-60 and CFU-L cells while a lower concentration of 4-HC (ie, 80 pmol/L) showed the same results on HL-60 of the optimal 4-HC concentration (100 pmolL) found in a previous After incubation of normal marrow with the immunochemotherapy protocol, CFU-GM and BFU-E were undetectable in most of the experiments by direct assay in semisolid medium. However, because infusion of chemopurified marrow containing no detectable CFU-GM produced hematologic recovery in transplanted patients3* this assay does not adequately predict the hematopoietic reconstitution capacity. Therefore, a more sensitive assay of early stem cell viability and capability to give rise to more mature progenitors is needed. Recent experimental evidences suggest that early hematopoietic progenitors with self-renewal property expressed CD34 antigen and that they are distinguishable from more differentiated myeloid cells?-' Furthermore, CD34+ cell fraction can be divided into distinct precursors populations according to the coexpression of HLA-DR and CD33 antigens. ' Andrews et a1 have recently demonstrated that only CD34+, CD33-cell population was able to sustain CFU cells (CFU-C) production for 5 weeks in long-term BM culture (LTMC) system while cells that expressed both the antigens generated few CFU-C. 39 The importance of CD34' cells is also underlined by studies showing that these cells, isolated by avidin-biotin immunoadsorption technique, can restore lymphohematopoiesis in lethally irradiated baboons and humans.8r9
More recently, Siena et al demonstrated that many CD34' cells are induced to circulate in the PB of cancer patients after high-dose chemotherapy and intravenous administration of rhuGM-CSF, and that the enrichment of CD34' cell fraction is a crucial point to ensure recovery of normal hematopoiesis after myeloablative chemotherapy.40 Therefore, we tried to assess the ability of the immunochemotherapeutic treatment to spare the putative hematopoietic precursors collected after positive selection by panning with monoclonal anti-MY10 antibody. A shortterm suspension culture system, which was shown specific to self renewal of pluripotent myeloid precursors in murine41,42 and human mode1,I7 was then set up and the increase in number and clonogenic efficiency of blast cells was assessed following stimulation with IL-3, IL-1 + IL-3, and MoCM. Our results demonstrated the recovery of the hematopoietic progenitors earlier than day-14 CFU-GM after immunochemotherapy. In particular, cultures containing both IL-1 and IL-3 or MoCM, in the absence of any preformed feeder layer, showed a marked increase in pluripotent precursors, whereas IL-3 used alone was less effective.
Finally, an experiment was addressed to compare the effect of two different combined protocols (4-HC used at 80 pmol/L v 100 pmol/L, which both gave the same results in terms of HL-60 clonogenic efficiency inhibition) on pluripotent stem cells. The lower dose of 4-HC allowed a better recovery of the hematopoietic progenitor compartment and the Delta value obtained was comparable with the values observed in a large series of experiments on normal BM samples where different techniques were used to ensure the optimal recovery and stimulation of early blast ~e1ls.l~ Further experiments are currently in progress to investigate the recovery of leukemic cells after immunochemotherapy and panning with anti-CD34 MoAb. In addition, the comparison between the LTMC system and our short-term liquid culture is underway to accurately quantitate pre-CFU-GM precursors.
In summary, our results showed that the combination of single cycle complement-mediated lysis by MoAbs and pharmacologic protocols can produce additive tumor cell For personal use only. on October 23, 2017. by guest www.bloodjournal.org From killing on leukemic cells while, under the same experimental conditions, early hematopoietic precursor are substantially spared. Conversely, in our experiments the depletion of the committed hematopoietic progenitors was nearly complete, suggesting, according to Rowley et al," the efficacy of our immunopharmacologic purging method in view of its clinical application. The responsiveness of early BM progenitors to IL-1 and IL-3 in combination also suggests that preincubation of autologous marrow with these cytokines may enhance the delayed hematopoietic reconstitution following the reinfusion of purged marrow.
Recent data from our laboratory support the use of IL-1 and IL-3 combination, which has been shown to expand the committed hematopoietic progenitor compartment without affecting the stem cell pool in the LTMC system.M Thus, the use of 4-HC + VP-16 and MoAbs would seem a reasonable approach to purge minimal residual leukemia from autologous graft.
